Skip to main content

Smith + Nephew Plc Value Stock - Dividend - Research Selection

Smith and nephew

ISIN: GB0009223206 , WKN: 502816

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery, various products, and technologies to assist in surgical treatment of the ear, nose, and throat; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Some Investors May Be Worried About Smith & Nephew's (LON:SN.) Returns On Capital

2024-03-18
When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...

7 Robotic Surgery Stocks to Buy for the Future of Healthcare

2024-03-13
There are some robotic surgery stocks for investors to buy in March this year. The growth of robotic-assisted surgery has been driven by its potential benefits, such as smaller incisions, reduced pain and scarring, quicker recovery times, and improved clinical outcomes. I think that investing in robotic surgery stocks is an underrated thematic choice for investors. The reason being is that there is currently a very low industry penetration of using robots in the surgical market, which means ther

Smith & Nephew plc Just Missed EPS By 38%: Here's What Analysts Think Will Happen Next

2024-03-01
Shareholders might have noticed that Smith & Nephew plc ( LON:SN. ) filed its annual result this time last week. The...

Smith & Nephew plc (NYSE:SNN) Q4 2023 Earnings Call Transcript

2024-02-28
Smith & Nephew plc (NYSE:SNN) Q4 2023 Earnings Call Transcript February 28, 2024 Smith & Nephew plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Deepak Nath: Good morning and welcome to the Smith & Nephew Q4 and Full Year ‘23 […]

Smith+Nephew and U.S. Army Institute of Surgical Research to engage in Master Cooperative Research and Development Agreement

2024-02-28
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announced they have entered into a Master Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR). This marks the first time that the USAISR has entered into a master agreement of this nature with an industry-leading medical technology company. The Master CRADA represents an enterprise-wide opportunity for Smith+Nephew across all business units - Advanced Wound

Smith & Nephew plc (SNN) Q4 2023 Earnings Call Transcript

2024-02-28
Smith & Nephew plc (NYSE:NYSE:SNN) Q4 2023 Earnings Conference Call February 27, 2024 3:30 AM ETCompany ParticipantsDeepak Nath - Chief Executive...

Smith & Nephew plc 2023 Q4 - Results - Earnings Call Presentation

2024-02-28
The following slide deck was published by Smith & Nephew plc in conjunction with their 2023 Q4 earnings call.

Health Care Roundup: Market Talk

2024-02-27
0751 GMT – The FTSE 100 index is expected to open 11 points, or 0.1%, lower at 7684.30, as equity markets pause after last week’s gains following very strong earnings from U.S. AI giant Nvidia as focus turns to economic data later in the week. “It feels like there is a moment of calm and silence in the aftermath of major tech earnings, investors will decide whether this rally deserves to continue higher straight away,” says Swissquote analyst Ipek Ozkardeskaya in a note. Investors await U.S. GDP data on Wednesday, then U.S. PCE inflation on Thursday and eurozone inflation data on Friday for potential further clues on the timing of interest-rate cuts.

Basic Materials Roundup: Market Talk

2024-02-27
0751 GMT – The FTSE 100 index is expected to open 11 points, or 0.1%, lower at 7684.30, as equity markets pause after last week’s gains following very strong earnings from U.S. AI giant Nvidia as focus turns to economic data later in the week. However, skepticism remains given that the expected recovery in the second half of 2023 didn’t materialize, the analysts say.

Are Investors Undervaluing Smith & Nephew SNATS (SNN) Right Now?

2024-02-21
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.